高危重度主动脉瓣狭窄患者自膨胀式TAVR与SAVR术后五年健康状况
基于CoreValve高危试验的随机对照研究,纳入713例高危重度主动脉瓣狭窄患者,比较自膨胀式经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换(SAVR)术后5年健康状况。结果显示,经股动脉TAVR组1个月时KCCQ评分改善优于SAVR组(差异16.8分,95%CI 12.4-21.2),但6个月后差异消失,5年时两组健康状况无显著差异;尽管5年死亡率较高,存活患者多数仍报告合理健康状况。
要点
- 经股动脉TAVR组1个月KCCQ改善优于SAVR,但6个月后差异消失。
- 非经股动脉入路患者各时间点TAVR与SAVR健康状况均无显著差异。
核心结论
- 在高危重度症状性主动脉瓣狭窄患者中,自膨胀式经股动脉TAVR相比SAVR有早期健康状况获益,但长期健康状况无差异。
- 尽管5年死亡率高,多数存活患者仍报告合理的健康状况。
研究设计与样本
- 随机临床试验,纳入45个美国临床中心的高外科风险重度主动脉瓣狭窄患者,完成基线KCCQ并随机接受自膨胀式TAVR或SAVR,2011年2月至2012年9月入组。
- 共713例患者,377例(53%)为男性,平均(SD)年龄83(7)岁。
- 采用重复测量协方差分析评估5年内KCCQ和12项简短健康调查的变化,因入路与治疗存在显著交互作用,所有分析按入路(经股动脉或非经股动脉)分层。
主要发现
- 基线平均(SD)KCCQ总体 summary 评分为47(23),提示健康状况严重受损。
- 经股动脉TAVR组1个月KCCQ总体 summary 评分改善优于SAVR组,差异16.8分(95%CI 12.4-21.2)。
- 6个月时早期治疗差异不再明显,此后两组健康状况无显著差异。
- 5年时经股动脉TAVR组44%(134/305)存活,SAVR组39%(105/266)存活。
临床怎么用
- 对于高危重度主动脉瓣狭窄患者,经股动脉TAVR可带来早期健康状况获益,但长期健康状况与SAVR相当。
- 临床决策时可考虑TAVR的早期获益,但需结合患者入路条件和长期预后综合评估。
局限性
- 研究对象为高危患者,结果不能外推至低危人群。
- 5年死亡率高,存活患者样本量减少,可能影响长期健康状态比较的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the CoreValve High-Risk Trial, patients with severe symptomatic aortic stenosis had similar clinical outcomes with transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) over 5 years of follow-up, with mortality rates of more than 50% in both groups. OBJECTIVE: To describe the long-term health status of surviving patients randomized to self-expanding TAVR vs SAVR. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included patients at high surgical risk with severe aortic stenosis who completed a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and were randomized to either self-expanding TAVR or SAVR from 45 US clinical sites. Patients were enrolled from February 2011 to September 2012. Analysis began May 2018 and ended June 2020. MAIN OUTCOMES AND MEASURES: Change in KCCQ and the 12-Item Short-Form Health Survey over 5 years, as assessed by repeated-measures analysis of covariance. Because there were significant interactions between access site and treatment for 1-month health status outcomes, all analyses were stratified by access site (iliofemoral or noniliofemoral). RESULTS: Of 713 patients, 377 (53%) were men, and the mean (SD) age was 83 (7) years. Prior to treatment, the mean (SD) KCCQ overall summary score (range, 0-100; higher score indicated better health status) was 47 (23), indicating substantial health status impairment. Among surviving patients, the KCCQ overall summary score increased significantly in both groups with greater early benefit with iliofemoral TAVR than SAVR (1-month difference, 16.8 points; 95% CI, 12.4-21.2). However, this early treatment difference between TAVR and SAVR was no longer apparent by 6 months, and there was no significant difference in health status between groups thereafter. At 5 years, 44% (134 of 305) of patients who underwent iliofemoral TAVR and 39% (105 of 266) who underwent SAVR were alive in this high-risk elderly cohort. Among surviving patients for whom health status data were available, 61% (48 of 79) in the TAVR group and 65% (46 of 71) in the SAVR group had KCCQ overall summary score more than 60 (P = .61). In the noniliofemoral cohort, there were no significant health status differences at any time between TAVR and SAVR. Results were similar for individual KCCQ domains and the Short-Form Health Survey. CONCLUSIONS AND RELEVANCE: In high-risk patients with severe symptomatic aortic stenosis, there was an early health status benefit with self-expanding iliofemoral TAVR vs SAVR but no difference between groups in long-term health status. Although mortality at 5 years was high in this population, the majority of surviving patients continued to report reasonable health status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01240902.
引用
- Arnold SV, Chinnakondepalli KM, Magnuson EA, et al. Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. JAMA Cardiol. 2021. PMID: 32997095. doi:10.1001/jamacardio.2020.4397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。